EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

LRRK2 mutations: at the crossroads of dopamine, iron, and calcium imbalance in Parkinson’s disease

Weronika Skarżyńska, Aleksandra Moskal iD, Jacek Kuźnicki

Acta Neurobiologiae Experimentalis · 24.04.2026

DOI: 10.55782/kre63y59 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Neurobiologiae Experimentalis, online erschienen am 24.04.2026. Verfasst von Weronika Skarżyńska und 2 weiteren Autor:innen. Beteiligte Einrichtung: International Institute of Molecular and Cell Biology in Warsaw, Poland. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, Iron, Dopamine. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons. The G2019S mutation in the leucine‑rich repeat kinase 2 (LRRK2) gene is the most common genetic cause of familial and sporadic PD. In dopaminergic neurons, increased kinase activity caused by LRRK2‑G2019S mutation impairs synaptic vesicle recycling and dopamine storage, increasing cytosolic dopamine, which is prone to oxidation and generates reactive oxygen species. Simultaneously, the mutation alters iron metabolism through Rab misregulation, increasing iron uptake and lysosomal dysfunction, further amplifying oxidative stress and creating a pro‑ferroptotic environment. At the same time, dysregulated calcium signaling, driven by the enhanced activity of L‑type calcium channels and impaired mitochondrial calcium buffering via the mitochondrial calcium uniporter, enhances mitochondrial dysfunction. This minireview integrates current evidence linking LRRK2‑G2019S to these pathological pathways, highlighting this mutation’s role in dopamine, iron, and calcium imbalance. Understanding this molecular interplay may provide novel insights into PD pathogenesis and guide the development of targeted neuroprotective therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson DiseaseIronDopamineMutationCalciumHumansAnimalsDopaminergic Neurons

Stichwörter der Autor:innen

LRRK2Parkinson’s diseasecalciumdopamineiron

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2IronDopamineCalciumLRRK2 protein, human

Autor:innen und Institutionen

  • International Institute of Molecular and Cell Biology in Warsaw, Poland.

ORCID-Profile: Aleksandra Moskal

Zitieren

APA

Skarżyńska, W., Moskal, A., & Kuźnicki, J. (2026). LRRK2 mutations: at the crossroads of dopamine, iron, and calcium imbalance in Parkinson’s disease. Acta Neurobiologiae Experimentalis. https://doi.org/10.55782/kre63y59

Vancouver

Skarżyńska W, Moskal A, Kuźnicki J. LRRK2 mutations: at the crossroads of dopamine, iron, and calcium imbalance in Parkinson’s disease. Acta Neurobiologiae Experimentalis. 2026. doi:10.55782/kre63y59

BibTeX
@article{Skaryska2026,
  author = {Skarżyńska, Weronika and Moskal, Aleksandra and Kuźnicki, Jacek},
  title = {LRRK2 mutations: at the crossroads of dopamine, iron, and calcium imbalance in Parkinson’s disease},
  journal = {Acta Neurobiologiae Experimentalis},
  year = {2026},
  doi = {10.55782/kre63y59}
}
Kostenlos starten →